Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO). Briones J, et al. Among authors: caballero d. Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. Haematologica. 2014. PMID: 24986878 Free PMC article. No abstract available.
Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
Sureda A, Mataix R, Hernández-Navarro F, Jarque I, Lahuerta JJ, Tomás JF, Brunet S, Caballero D, Conde E, León A, Fernández MN, López A, Maldonado J, Bengoechea E, Callís M, Carrera D, García-Conde J, García-Laraña J, Moraleda JM, Morey M, Rifón J, Sierra J, Torres A, Domingo-Albós A. Sureda A, et al. Among authors: caballero d. Bone Marrow Transplant. 1997 Aug;20(4):283-8. doi: 10.1038/sj.bmt.1700886. Bone Marrow Transplant. 1997. PMID: 9285542
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
Lahuerta JJ, Martinez-Lopez J, Grande C, Bladé J, de la Serna J, Alegre A, García-Laraña J, Caballero D, Sureda A, de la Rubia J, Alvarez AM, Marín J, Escudero A, Conde E, Perez-Equiza K, García Ruiz JC, Moraleda JM, León A, Bargay J, Cabrera R, Hernandez-García MT, Diaz-Mediavilla J, Miguel JS. Lahuerta JJ, et al. Among authors: caballero d. Br J Haematol. 2000 Apr;109(1):138-47. doi: 10.1046/j.1365-2141.2000.01979.x. Br J Haematol. 2000. PMID: 10848793 Free article.
Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies.
Brunet S, Urbano-Ispizua A, Ojeda E, Ruiz D, Moraleda JM, Díaz MA, Caballero D, Bargay J, de la Rubia J, Solano C, Zuazu J, Diez JL, de la Serna J, Espigado I, Alegre A, Torres JP, Jurado M, Fernández M, Vivancos P, Carreras E, Hernández F, Maldonado J, Sierra J, Rozman C; Spanish Group of Allogenic-PBT, Spain. Brunet S, et al. Among authors: caballero d. Br J Haematol. 2001 Sep;114(3):544-50. doi: 10.1046/j.1365-2141.2001.03002.x. Br J Haematol. 2001. PMID: 11552978 Free article.
Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation.
Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de La Rubia J, Bargay J, Caballero D, Díez-Martín JL, Ojeda E, Pérez de Oteiza JP, Ferrá C, Espigado I, Alegre A, de La Serna J, Torres P, Riu C, Odriozola J, Rozman C, Sierra J, García-Conde J, Montserrat E; Spanish Group of Allo-PBT. Urbano-Ispizua A, et al. Among authors: caballero d. Bone Marrow Transplant. 2001 Aug;28(4):349-54. doi: 10.1038/sj.bmt.1703154. Bone Marrow Transplant. 2001. PMID: 11571506
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, García-Laraña J, De La Rubia J, Sureda A, Vidal MJ, Escudero A, Pérez-Esquiza E, Conde E, García-Ruiz JC, Cabrera R, Caballero D, Moraleda JM, Leon A, Besalduch J, Hernandez MT, Rifon J, Hernandez F, Solano C, Palomera L, Parody R, Gonzalez JD, Mataix R, Maldonado J, Constela J, Carrera D, Bello JL, De Pablos JM, Pérez-Simón JA, Torres JP, Olanguren J, Prieto E, Acebede G, Peñarrubia MJ, Torres P, Díez-Martín JL, Rivas A, Sánchez JM, Díaz-Mediavilla J. San Miguel JF, et al. Among authors: caballero d. Hematol J. 2000;1(1):28-36. doi: 10.1038/sj.thj.6200003. Hematol J. 2000. PMID: 11920166
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Moscardó F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C, Solano C, Pimentel P, Pérez de Oteyza J, Ferrá C, Díez-Martín JL, Zuazu J, Espigado I, Campilho F, Arbona C, Moraleda JM, Mateos MV, Sierra J, Talarn C, Sanz MA. Moscardó F, et al. Among authors: caballero d. Exp Hematol. 2003 Jun;31(6):545-50. doi: 10.1016/s0301-472x(03)00070-5. Exp Hematol. 2003. PMID: 12829031 Free article. Clinical Trial.
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R, Pérez-Simón JA, Moreno E, Queraltó JM, Caballero D, Mateos M, Sureda A, Cañizo C, Brunet S, Briones J, Vazquez L, Clopés A, San Miguel JF, Sierra J. Martino R, et al. Among authors: caballero d. Biol Blood Marrow Transplant. 2005 Jun;11(6):437-47. doi: 10.1016/j.bbmt.2005.03.003. Biol Blood Marrow Transplant. 2005. PMID: 15931632 Free article.
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D, García-Marco JA, Martino R, Mateos V, Ribera JM, Sarrá J, León A, Sanz G, de la Serna J, Cabrera R, González M, Sierra J, San Miguel J. Caballero D, et al. Clin Cancer Res. 2005 Nov 1;11(21):7757-63. doi: 10.1158/1078-0432.CCR-05-0941. Clin Cancer Res. 2005. PMID: 16278397
304 results